Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA

NCT ID: NCT01550510

Last Updated: 2025-05-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-12-31
• Study Completion Date: 2015-02-28

Brief Summary

This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with irinotecan versus treatment with irinotecan alone in patients with recurrent or advanced colorectal cancer who have failed at least one treatment regimen with a 5-FU based therapy. This study will be conducted as an amendment to Investigational New Drug # 77486.

Detailed Description

Phase I: To assess whether or not (IV) Ascorbic Acid (AA) with irinotecan therapy is relatively safe and well-tolerated. This aim will be assessed by enrolling a minimum of 6 subjects meeting inclusion criteria, using a modified 3+3 design. Safety will be assessed with the following: toxicity graded by the NCI CTC, urinalysis pre- and post-infusion, basic metabolic panel, and CBC. From our experience and in the experience of our study collaborators, we hypothesize that the combination of IV AA with irinotecan will not be associated with adverse events.

Phase II: To utilize CT or PET/CT (when available) scans to evaluate disease progression to assess overall tumor response rate (complete and partial response) in subjects with advanced or recurrent colorectal cancer treated with the combination of ascorbic acid and irinotecan versus irinotecan alone.

Conditions

Stage IV Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ascorbic Acid + Irinotecan

Ascorbic Acid (50-100g, 3x weekly) with 350mg/m2 irinotecan once a week every 3 weeks

Group Type: EXPERIMENTAL

Ascorbic Acid

Intervention Type: DRUG

3x a week for 9 weeks

Irinotecan

Intervention Type: DRUG

350mg/m2 once a week every 3 weeks

Standard of Care (irinotecan alone)

350mg/m2 irinotecan once a week every 3 weeks

Group Type: ACTIVE_COMPARATOR

Irinotecan

Intervention Type: DRUG

350mg/m2 once a week every 3 weeks

Interventions

Ascorbic Acid

3x a week for 9 weeks

Intervention Type: DRUG

Irinotecan

350mg/m2 once a week every 3 weeks

Intervention Type: DRUG

Other Intervention Names

Ascorbate; Vitamin C; Camptothecin-11; CPT-11

Eligibility Criteria

Inclusion Criteria

• Age > 18 years
• Metastatic colorectal carcinoma (stage IV disease).
• Patients must have progressed on one or more prior chemotherapy treatment regimens including at least one trial of a 5-FU/oxaliplatin based therapy (FOLFOX) in combination with bevacizumab. Patients must not have had standard chemotherapy within at least 2 weeks of beginning ascorbic acid treatment provided that they have recovered from any toxicities that they experienced.
• G6PD status > lower limit of normal
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
• Laboratory at baseline evaluation for inclusion in the study: creatinine ≤1.5X upper limit (if the creatinine is elevated, but ≤1.5X the ULN, a 24 hour creatinine clearance will be obtained); transaminase (AST/ALT) ≤2.0X upper limit of normal; bilirubin levels ≥ 2 mg/dL; ANC ≥1,500/mm3; Hemoglobin > 8g/dL; platelet ≥ 100,000/mm3;
• Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the study.
• Willing and able to provide informed consent and participate in the study procedures.

Exclusion Criteria

• Patients with evidence of a significant current psychiatric disorder that would prevent completion of the study as determined by the PI will not be allowed to participate.
• Co-morbid medical condition that would affect survival or tolerance as determined by the PI. This includes patients who have not fully recovered from toxicities associated with prior therapy. It also includes subjects who, as determined by the PI, are at risk of experiencing fluid overload (i.e., congestive heart failure).
• Patients who currently abuse alcohol or drugs.
• Patients with known glomerular filtration rate of <60ml/min or with nephrotic range proteinuria.
• Pregnant or lactating women
• Enrollment in active clinical trial/ experimental therapy or IND study within the prior 30 days.
• Contraindication for CT or PET/CT as per the PI.
• Patients who are on strong inducers of CYP3A4 which include but are not limited to: Aminoglutethimide, Bexarotene, Bosentan, Carbamazepine, Dexamethasone, Efavirenz, Fosphenytoin, Griseofulvin, Modafinil, Nafcillin, Nevirapine, Oxcarbazepine, Phenobarbital, Phenytoin, Primidone, Rifabutin, Rifampin, Rifapentine, St. John's wort.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Thomas Jefferson University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel A Monti, MD

Role: PRINCIPAL_INVESTIGATOR

Thomas Jefferson University

Locations

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Countries

United States

Related Links

http://hospitals.jefferson.edu/

Thomas Jefferson University Hospital

Other Identifiers

JT 1548

Identifier Type: OTHER

Identifier Source: secondary_id

11D.459

Identifier Type: -

Identifier Source: org_study_id